Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Publication year range
1.
Probl Radiac Med Radiobiol ; 25: 443-455, 2020 Dec.
Article in English, Ukrainian | MEDLINE | ID: mdl-33361853

ABSTRACT

OBJECTIVE: Describe and characterize the peculiarities of the chronic myeloid leukemia (CML) course and responseto treatment in patients irradiated as a result of the Chornobyl nuclear power plant (ChNPP) accident based on theassessment of clinical-laboratory and clinical parameters. MATERIALS AND METHODS: The CML patients (n = 33) exposed to ionizing radiation as a result of the ChNPP accidentwere enrolled. The comparison group consisted of CML patients (n = 725) with no history of radiation exposure. Allpatients were in the chronic phase of the disease. Clinical, hematological and molecular genetic research methodswere applied. RESULTS: Patients exposed to ionizing radiation as a result of the ChNPP accident had no differences in CML manifestation, as well as in classical genetic markers at the onset of the disease compared with patients with no historyof radiation exposure. Reduction of tumor clone on imatinib therapy was significantly less effective in the patientsexposed to ionizing radiation than in cases of no history of radiation exposure. Cases of primary resistance were statistically significantly prevalent in the ChNPP accident consequences clean-up workers while in the residents ofradiologically contaminated areas a statistically significant increase in probability of loss of complete cytogeneticresponse (development of secondary resistance) to imatinib therapy was found. An association was found betweenthe radiation exposure and probability of loss of complete cytogenetic response to imatinib therapy in this group ofpatients. CONCLUSION: The radiation exposure in the history even many years before the onset of CML is an unfavorable exogenous factor responsible for the development of resistance to imatinib therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chernobyl Nuclear Accident , Fusion Proteins, bcr-abl/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Radiation Exposure/adverse effects , Radiation Injuries/genetics , Aged , Air Pollutants, Radioactive/adverse effects , Bone Marrow Cells/immunology , Bone Marrow Cells/pathology , Bone Marrow Cells/radiation effects , Chromosomes, Human, Pair 22 , Chromosomes, Human, Pair 9 , Drug Resistance, Neoplasm/genetics , Emergency Responders , Female , Food Contamination, Radioactive , Gene Expression , Humans , Imatinib Mesylate/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality , Male , Middle Aged , Prognosis , Radiation Injuries/drug therapy , Radiation Injuries/etiology , Radiation Injuries/mortality , Radiation, Ionizing , Soil Pollutants, Radioactive/adverse effects , Survival Analysis , Translocation, Genetic , Ukraine
SELECTION OF CITATIONS
SEARCH DETAIL
...